Singapore-based clinical-stage biotechnology company AUM Biosciences plans to go public in the US through a merger with Mountain Crest Acquisition Corp V, a publicly-traded special purpose acquisition company, in a transaction that reflects a pre-money equity value of $400 million for AUM, according to a statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
